General Application
LP-300

Patent Title
Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer (PCT/US20/21615)

Patent Summary
NSCLC and Female (non/never smokers)

Countries
US, Australia, Canada, Brazil, Mexico, Japan, China, India, Singapore, Korea, EU, Hong Kong,

Priority Date
2021-09-08  

‍

General Application
LP-300

Patent Title
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds (14/675,607)

Patent Summary
NSCLC

Countries
US

Priority Date
2021-03-03  

‍

General Application
LP-300

Patent Title
method for determining sensitivity to 2,2'-dithio-bis-ethane sulfonate with nrf2 (PCT/US21/12994)

Patent Summary
Solid Tumors

Countries
Australia, Canada, Mexico, China, Japan, US, EU, Korea

Priority Date
2022-07-11  

‍

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof

Patent Summary

Augmentation of anti-cancer activity

Patent No./Application No.

China ZL200780017354

Countries

China, Australia

Priority Date

2007-03-16

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

Patent Summary

The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Patent No./Application No.

US Patent Nos. 7829540, 7829539, 7829117, 7829538 & 7235589

Countries

France, UK and US

Priority Date

2007-11-14

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Chemoprotective methods and compositions

Patent Summary

Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.

Patent No./Application No.

CA2648945

Countries

Australia, Canada, China, Denmark, France, Germany, Hungary, Ireland, Italy, Japan, Netherlands,  Sweden, Switzerland, and UK

Priority Date

2006-12-13

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Patent Summary

LP-300

Patent No./Application No.

US9320760

Countries

US

Priority Date

2008-07-15

General Application

Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)

Patent Title

Increasing cancer patient survival time by administration of dithio-containing compounds

Patent Summary

LP-300

Patent No./Application No.

US9023805

Countries

US

Priority Date

2010-09-16

General Application
LP-184

Patent Title
Lyophilized illudins and analogs

Patent Summary
LP-184/284 lyophilized products

Countries
TW, PCT

Priority Date
2024-10-01  

‍

‍

General Application
LP-184

Patent Title
Treating liver cancers with hydroxyureamethyl acylfulvene (PCT/US24/43699)

Patent Summary
LP-184 and liver cancer

Countries
TBD

Priority Date
2024-09-03  

‍

General Application
LP-184

Patent Title
Cancer drug sensitivity determining markers (PCT/US21/72496)

Patent Summary
Solid Tumors

Countries
US, Mexico, Canada, Japan, China, Australia, EU, Korea

Priority Date
2023-05-18  

‍

General Application
LP-184

Patent Title
Method for treating renal cell carcinoma or cancer (PCT/US24/19456)

Patent Summary
LP-184 and Renal Cancer

Countries
TBD

Priority Date
2024-03-22  

‍

General Application
LP-184

Patent Title
Method for treating breast cancers and PARP resistant breast cancers (PCT/US23/70328)

Patent Summary
LP-184 and PARP Resistant Breast Cancer

Countries
US, Japan, Canada, EU, Australia

Priority Date
2022-07-15

‍

General Application
LP-184

Patent Title
Method for treating tumors with hydroxyureamethyl acylfulvene and radiation (PCT/US2022/080150)

Patent Summary
LP-184 and Radiation

Countries
US, Canada, Mexico, Japan, China, EU, Australia

Priority Date
2021-11-18

‍

General Application
LP-184

Patent Title
Treating cancers with combinations of PARP inhibitor and acylfulvenes

Patent Summary
LP-184 and PARP Inhibitors

Countries
US, Canada, Mexico, Japan, EU

Priority Date
2021-07-29

General Application
LP-184

Patent Title
Methods for treating cancers with spironolactone and acylfulvenes

Patent Summary
LP-184 and Spironolactone

Countries
US, Canada, China, Mexico, Japan, EU, Australia, Korea

Priority Date
2021-07-29

‍

General Application
LP-184

Patent Title
Method for Treating Lung Cancer and Non-Small Cell Lung Cancer (PCT/US22/71676)

Patent Summary
Lung cancer and NSCLC

Countries
US, Canada, Mexico, Korea, Japan, China, Australia, EU

Priority Date
2023-10-02  

‍

General Application
LP-184

Patent Title
Method for treating rhabdoid tumor

Patent Summary
Rhabdoid Tumor

Countries
US, EU, Canada, Japan, Australia

Priority Date
2022-05-11  

‍

General Application
LP-184

Patent Title
Treatment of Brain Metastasis Using Illudins or HydroxyUreaMethyl Acylfulvene

Patent Summary
Brain Cancer Metastatsis

Countries
US, Canada, Japan, Mexico, Brazil, China, Korea, US, EU

Priority Date
2023-07-17  

‍

General Application
LP-184

Patent Title
HYDROXYUREAMETHYL-ACYLFUL VENE FOR TREATING BRAIN CANCER OR CNS CANCER (PCT/US202 l/026907)

Patent Summary
Brain Cancer and CNS

Countries
Japan, Canada, China, Brazil, Korea, Australia, EU, Mexico

Priority Date
2022-10-17  

‍

General Application
LP-184

Patent Title
Method for treating pancreatic cancer (PCT/US2021/031606)

Patent Summary
Pancreatic Cancer

Countries
Japan, Brazil, Canada, Mexico, China, Korea, Australia, EU, US

Priority Date
2022-10-04  

‍

General Application
LP-184

Patent Title
Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers

Patent Summary
Solid Tumors

Countries
US, Canada, EU, Japan, China, Australia, Hong Kong

Priority Date
2021-04-06  

‍

General Application
LP-184

Patent Title
Illudins Analogs (PCT/US19/49555)

Patent Summary
LP-184 Molecule

Countries
US, EU, Canada, India, Japan, Mexico, China, Korea, Australia

Priority Date
2021-03-01  

‍

General Application

Irofulven

Patent Title

Illudin analogs useful as anticancer agents

Patent Summary

acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment

Patent No./Application No.

US7655695

Countries

EP1909783B1 (Germany, France, and Great Britain), JP4989648 (US is Priority Application)

Priority Date

2/2/10

General Application

Next Generation Illudins

Patent Title

Illudin analogs, used thereof, and methods for synthesizing the same

Patent Summary

This application is directed to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof.  A new and potentially more potent illudin is disclosed in this application.

Patent No./Application No.

PCT/US19/49555

Countries

US and other countries TBD

Priority Date

2018-09-04